pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Characteristics of included studies and demographic of patients

No. Study Country Study design Study period N (M/F) Age (years)1 Dose of zinc Treatment


Zinc Control Zinc Control
1 Jasper Seth Yao et al. 2020 Finland Retrospective observational study 2020.04.11 - 2020.04.21 196 (110/86) 46 (28/18) 65 [53-77] 71 [58-84] 100 mg daily -
2 Jennifer A Frontera et al. 2020 USA Multicenter cohort study 2020.03.10 - 2020.05.20 1,006 (604/402) 2,467 (1,344/1,123) 64 [53-74] 64 [49-76] 50 mg once or twice daily zinc + hydroxychloroquine
3 Philip M Carlucci et al. 2020 USA Retrospective observational study 2020.03.02 - 2020.04.11 411 (264/147) 521 (320/201) 63.19 ± 15.18 61.83 ± 15.97 50 mg twice daily for 5 days zinc + hydroxychloroquine + azithromycin
4 Sherief Abd-Elsalam et al. 2020 Egypt Randomized controlled trial 2020.06.23 – 2020.08.23 96 (52/44) 95 (64/31) 43.48 ± 14.62 46.64 ± 13.17 50 mg twice daily for 5 days zinc + hydroxychloroquine

1 presented as median [Interquartile Range] or mean±standard deviation

Korean J Clin Pharm 2021;31:136-44 https://doi.org/10.24304/kjcp.2021.31.2.136
© 2021 Korean J Clin Pharm